Friday 6 November 2026 Export SUPN’s income statement to Excel — free account

Indivior Pharmaceuticals Inc.

SUPN Healthcare Drug Manufacturers Specialty & Generic

Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.

Revenue: +13.4%
EPS: +241.5%
Free cash flow: +240.7%
Total debt: +51.6%

Quarter to September 2026, against a year earlier

28.21 0.06 +0.21%

Follow SUPN

Alert me

Market cap: $5.6B
P/E: 7.6×
Fwd P/E: 9.5×
Dividend yield: 0.00%
F-score: 4/9
Altman Z: 3.28
Beneish M: −1.52
Dividend safety: n/a

Overview

Indivior Pharmaceuticals Inc. (SUPN) Price to free cash flow

Alert me on Price to free cash flow

As of 4 November 2026, Indivior Pharmaceuticals Inc. (SUPN) trades at a price to free cash flow of 115×. Over the past ten years it has ranged from 0.0× (September 2026) to 330× (January 2025); the current reading is higher than 97% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 16.3× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/SUPN/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Indivior Pharmaceuticals Inc. price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/SUPN/metrics/price-to-free-cash-flow">Indivior Pharmaceuticals Inc. (SUPN) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	0.0×	—
FY2024	328×	—
FY2023	0.0×	—
FY2022	0.0×	—
FY2021	7.5×	—
FY2020	0.0×	—
FY2019	2.6×	(21.32%)
FY2018	3.3×	(80.38%)
FY2017	16.7×	140.99%
FY2016	6.9×	3.04%

Period	Price to free cash flow	Change
Sep 2026	146×	—
Jun 2026	0.0×	—
Mar 2026	0.0×	—
Dec 2025	0.0×	—
43 more quarters	Free account

Against its own ten years

Low 0.0× High 330×

Ten-year median 6.6×

Current reading's percentile 97

Company	Price to free cash flow
AMRX AMNEAL PHARMACEUTICALS, INC. compare	n/m
AMLX Amylyx Pharmaceuticals, Inc. compare	n/m
LNTH Lantheus Holdings, Inc. compare	16.9×
LQDA Liquidia Corporation compare	26.4×
ALKS Alkermes plc compare	32.8×
KNSA Kiniksa Pharmaceuticals International, plc compare	35.1×
HIMS Hims & Hers Health, Inc. compare	67.3×
SUPN Indivior Pharmaceuticals Inc.	115×
RDY Dr. Reddy's Laboratories Ltd compare	126×
Drug Manufacturers Specialty & Generic industry median	16.3×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Indivior Pharmaceuticals Inc. (SUPN) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on SUPN

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on SUPN

Stockrow Weekly